• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Gemini Therapeutics Inc. (Amendment)

    11/13/23 6:46:57 AM ET
    $GMTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GMTX alert in real time by email
    SC 13D/A 1 d538454dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)*

     

     

    Disc Medicine, Inc.

    (Name of Issuer)

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

    254604101

    (CUSIP Number)

    Alejandro Moreno

    Langhorne S. Perrow

    c/o Access Industries, Inc.

    40 West 57th Street, 28th Floor

    New York, New York 10019

    (212) 247-6400

    with copies to:

    Nicholas P. Pellicani

    Debevoise & Plimpton LLP

    65 Gresham Street

    EC2V 7NQ

    London

    + 44 20 7786 9000

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    November 9, 2023

    (Date of Event which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rules 13d-1(e), 13d-1(f) or 13d-1(g), check the following box.  ☐

     

     

     


    CUSIP No. 254604101

     

      1    

      NAME OF REPORTING PERSON.

     

      AI DMI LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

      (a)  ☐        (b)  ☐

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

      SC, AF

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      State of Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      SOLE VOTING POWER

     

      3,345,840 shares(1)

         8  

      SHARED VOTING POWER

     

      0 shares

         9  

      SOLE DISPOSITIVE POWER

     

      3,345,840 shares(1)

       10  

      SHARED DISPOSITIVE POWER

     

      0 shares

      11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      3,345,840 shares(1)

      12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

      13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11);

     

      13.74%(2)

      14  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      OO (Limited Liability Company)

     

    (1)

    Represents (i) 3,141,759 shares of Common Stock and (ii) 204,081 pre-funded warrants to purchase shares of Common Stock at $0.0001 per share (the “Pre-Funded Warrants”).

    (2)

    Based on 24,344,509 shares of Common Stock consisting of (i) 24,140,428 shares of Common Stock outstanding as of November 7, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 9, 2023, and (ii) 204,081 shares of Common Stock underlying the Pre-Funded Warrants.


    CUSIP No. 254604101

     

      1    

      NAME OF REPORTING PERSON.

     

      Access Industries Holdings LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

      (a)  ☐        (b)  ☐

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

      SC, AF

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States of America

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      SOLE VOTING POWER

     

      0 shares

         8  

      SHARED VOTING POWER

     

      3,345,840 shares(1)

         9  

      SOLE DISPOSITIVE POWER

     

      0 shares

       10  

      SHARED DISPOSITIVE POWER

     

      3,345,840 shares(1)

      11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      3,345,840 shares(1)

      12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

      13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11);

     

      13.74%(2)

      14  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      OO (Limited Liability Company)

     

    (1)

    Represents (i) 3,141,759 shares of Common Stock and (ii) 204,081 Pre-Funded Warrants.

    (2)

    Based on 24,344,509 shares of Common Stock consisting of (i) 24,140,428 shares of Common Stock outstanding as of November 7, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 9, 2023, and (ii) 204,081 shares of Common Stock underlying the Pre-Funded Warrants.


    CUSIP No. 254604101

     

      1    

      NAME OF REPORTING PERSON.

     

      Access Industries Management, LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

      (a)  ☐        (b)  ☐

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

      SC, AF

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      State of Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      SOLE VOTING POWER

     

      0 shares

         8  

      SHARED VOTING POWER

     

      3,345,840 shares(1)

         9  

      SOLE DISPOSITIVE POWER

     

      0 shares

       10  

      SHARED DISPOSITIVE POWER

     

      3,345,840 shares(1)

      11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      3,345,840 shares(1)

      12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

      13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11);

     

      13.74%(2)

      14  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      OO (Limited Liability Company)

     

    (1)

    Represents (i) 3,141,759 shares of Common Stock and (ii) 204,081 Pre-Funded Warrants.

    (2)

    Based on 24,344,509 shares of Common Stock consisting of (i) 24,140,428 shares of Common Stock outstanding as of November 7, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 9, 2023, and (ii) 204,081 shares of Common Stock underlying the Pre-Funded Warrants.


    CUSIP No. 254604101

     

      1    

      NAME OF REPORTING PERSON.

     

      Len Blavatnik

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

      (a)  ☐        (b)  ☐

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

      SC, AF

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States of America

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      SOLE VOTING POWER

     

      0 shares

         8  

      SHARED VOTING POWER

     

      3,345,840 shares(1)

         9  

      SOLE DISPOSITIVE POWER

     

      0 shares

       10  

      SHARED DISPOSITIVE POWER

     

      3,345,840 shares(1)

      11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      3,345,840 shares(1)

      12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

      13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11);

     

      13.74%(2)

      14  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      IN

     

    (1)

    Represents (i) 3,141,759 shares of Common Stock and (ii) 204,081 Pre-Funded Warrants.

    (2)

    Based on 24,344,509 shares of Common Stock consisting of (i) 24,140,428 shares of Common Stock outstanding as of November 7, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 9, 2023, and (ii) 204,081 shares of Common Stock underlying the Pre-Funded Warrants.


    CONTINUATION PAGES TO AMENDMENT NO. 3 TO SCHEDULE 13D

    This Amendment No. 3 to Schedule 13D is being filed by AI DMI LLC (“AI DMI”), Access Industries Holdings LLC (“AIH”), Access Industries Management, LLC (“AIM”) and Len Blavatnik (collectively, the “Reporting Persons”, and each, a “Reporting Person”), in respect of the common stock, par value $0.0001 per share (the “Common Stock”), of Disc Medicine, Inc. (the “Issuer”).     The shares of Common Stock of the Issuer are listed on the Nasdaq Global Market under the symbol “IRON.”

    The Schedule 13D filed by the Reporting Persons with the Securities and Exchange Commission (the “SEC”) on January 9, 2023, as amended and supplemented by Amendment No. 1 to the Schedule 13D filed by the Reporting Persons with the SEC on February 17, 2023 and Amendment No. 2 to the Schedule 13D filed by the Reporting Persons with the SEC on June 20, 2023 (together, the “Schedule”), is hereby amended and supplemented by the Reporting Persons as set forth below in this Amendment No. 3. This amendment is filed by the Reporting Persons in accordance with Rule 13d-2 of the Securities Exchange Act of 1934, as amended, and refers only to information that has materially changed since the filing of the Schedule. The items identified below, or the particular paragraphs of such items which are identified below, are amended as set forth below. Unless otherwise indicated, all capitalized terms used and not defined herein have the respective meanings assigned to them in the Schedule.

     

    Item 5

    Interest in Securities of the Issuer

    Item 5 to the Schedule is hereby amended and restated as follows:

    (a) and (b) The responses of each of the Reporting Persons with respect to Rows 11, 12, and 13 of the cover pages of this Schedule 13D that relate to the aggregate number and percentage of Common Stock (including but not limited to footnotes to such information) are incorporated herein by reference.

    The responses of each of the Reporting Persons with respect to Rows 7, 8, 9, and 10 of the cover pages of this Schedule 13D that relate to the number of shares of Common Stock as to which each of the persons or entities referenced in Item 2 above has sole or shared power to vote or to direct the vote of and sole or shared power to dispose of or to direct the disposition of (including but not limited to footnotes to such information) are incorporated herein by reference.

    3,141,759 shares of Common Stock and 204,081 Pre-Funded Warrants are owned directly by AI DMI and may be deemed to be beneficially owned by AIH, AIM and Mr. Blavatnik because (i) Len Blavatnik controls AIM and holds a majority of the outstanding voting interests in AIH, (ii) AIM controls AIH and (iii) AIH indirectly controls all of the outstanding voting interests in AI DMI. Each of the Reporting Persons (other than AI DMI), and each of their affiliated entities and the officers, partners, members and managers thereof, disclaims beneficial ownership of these securities.

    (c) The following transactions in the Issuer’s securities have been effected by Reporting Persons within the 60 days prior to this filing:

    None.

    (d) Not applicable.

    (e) Not applicable.


    Item 7

    Materials to Be Filed as Exhibits

    The disclosure in Item 7 is hereby supplemented by adding the following in appropriate numerical order:

     

    Exhibit    Description
    99.10    Joint Filing Agreement, dated as of November 13, 2023.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: November 13, 2023

     

    AI DMI LLC     By: Access Industries Management, LLC, its Manager
        /s/ Alejandro Moreno
        Name: Alejandro Moreno
        Title: Executive Vice President
    ACCESS INDUSTRIES HOLDINGS LLC     By: Access Industries Management, LLC, its Manager
        /s/ Alejandro Moreno
        Name: Alejandro Moreno
        Title: Executive Vice President
    ACCESS INDUSTRIES MANAGEMENT, LLC     /s/ Alejandro Moreno
        Name: Alejandro Moreno
        Title: Executive Vice President
        /s/ *
        Name: Leonard Blavatnik

     

     

    *

    The undersigned, by signing his name hereto, executes this Schedule 13D pursuant to the Limited Power of Attorney executed on behalf of Mr. Blavatnik and filed herewith.

     

    By:

     

    /s/ Alejandro Moreno

     

    Name: Alejandro Moreno

     

    Attorney-in-Fact

     

    Get the next $GMTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GMTX

    DatePrice TargetRatingAnalyst
    3/11/2022$5.00 → $2.00Buy → Neutral
    HC Wainwright & Co.
    3/3/2022$10.00 → $2.00Outperform → Market Perform
    SVB Leerink
    3/1/2022$23.00 → $1.50Buy → Hold
    Jefferies
    1/24/2022$15.00 → $10.00Outperform
    SVB Leerink
    12/20/2021$25.00 → $15.00Outperform
    SVB Leerink
    12/15/2021$20.00Buy
    HC Wainwright & Co.
    10/6/2021$20.00 → $18.00Buy
    Goldman Sachs
    More analyst ratings

    $GMTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Franchi Jean M. was granted 36,666 shares (SEC Form 4)

      4 - Disc Medicine, Inc. (0001816736) (Issuer)

      2/15/24 8:37:53 PM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Franchi Jean M.

      3 - Disc Medicine, Inc. (0001816736) (Issuer)

      2/15/24 8:33:28 PM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bitterman Kevin sold $6,934,125 worth of shares (102,500 units at $67.65) (SEC Form 4)

      4 - Disc Medicine, Inc. (0001816736) (Issuer)

      1/25/24 4:33:04 PM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GMTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Disc Medicine Receives FDA Orphan Drug Designation for Bitopertin for the Treatment of Erythropoietic Protoporphyria

      WATERTOWN, Mass., Dec. 27, 2022 /PRNewswire/ -- Disc Medicine, Inc. ("Disc"), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that the U.S. Food and Drug Administration ("FDA") granted Orphan Drug Designation to bitopertin for the treatment of erythropoietic protoporphyria ("EPP"). Bitopertin is an investigational oral, selective inhibitor of glycine transporter 1 ("GlyT1") designed to modulate heme biosynthesis, and has been shown in preclinical studies to reduce accumulation of protoporphyrin IX ("PPIX"), the toxic metabolite that causes dise

      12/27/22 8:00:00 AM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Disc Medicine Announces Several Presentations Across Hematology Portfolio at the 64th American Society of Hematology Annual Meeting

      WATERTOWN, Mass., Dec. 13, 2022 /PRNewswire/ -- Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients living with serious hematologic diseases, presented five posters spanning several of its hematology programs at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition held in New Orleans, LA. "Disc Medicine continues to make considerable progress towards the development of potentially first-in-class therapeutic candidates for hematologic disorders," said John

      12/13/22 9:00:00 AM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Disc Medicine Announces Multiple Presentations Across Hematology Portfolio at the 64th American Society of Hematology Annual Meeting

      CAMBRIDGE, Mass., Nov. 3, 2022 /PRNewswire/ -- Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that five abstracts related to several of its hematology programs have been accepted for poster presentation at the upcoming 64th American Society of Hematology (ASH) Annual Meeting and Exposition, which will be held in New Orleans, LA on December 10-13, 2022.  "We are pleased to have five abstracts selected for presentat

      11/3/22 9:00:00 AM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GMTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Gemini Therapeutics downgraded by HC Wainwright & Co. with a new price target

      HC Wainwright & Co. downgraded Gemini Therapeutics from Buy to Neutral and set a new price target of $2.00 from $5.00 previously

      3/11/22 6:36:28 AM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gemini Therapeutics downgraded by SVB Leerink with a new price target

      SVB Leerink downgraded Gemini Therapeutics from Outperform to Market Perform and set a new price target of $2.00 from $10.00 previously

      3/3/22 6:29:25 AM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gemini Therapeutics downgraded by Jefferies with a new price target

      Jefferies downgraded Gemini Therapeutics from Buy to Hold and set a new price target of $1.50 from $23.00 previously

      3/1/22 6:13:52 AM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GMTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Gemini Therapeutics Inc. (Amendment)

      SC 13G/A - Disc Medicine, Inc. (0001816736) (Subject)

      2/14/24 4:08:06 PM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Gemini Therapeutics Inc. (Amendment)

      SC 13G/A - Disc Medicine, Inc. (0001816736) (Subject)

      2/13/24 6:51:49 PM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Gemini Therapeutics Inc. (Amendment)

      SC 13G/A - Disc Medicine, Inc. (0001816736) (Subject)

      2/9/24 8:50:22 AM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GMTX
    SEC Filings

    See more
    • Gemini Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Disc Medicine, Inc. (0001816736) (Filer)

      2/7/24 8:10:55 AM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Gemini Therapeutics Inc.

      144 - Disc Medicine, Inc. (0001816736) (Subject)

      1/23/24 5:47:19 PM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Gemini Therapeutics Inc.

      144 - Disc Medicine, Inc. (0001816736) (Subject)

      1/23/24 5:44:49 PM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GMTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Gemini Therapeutics Provides Corporate Update

      Gemini Therapeutics, Inc. (NASDAQ:GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today provided a corporate update announcing a leadership transition, strategic evaluation and corporate restructuring. The Board of Directors has appointed Georges Gemayel, Ph.D., the Company's current Executive Chair, as interim President and Chief Executive Officer to succeed Jason Meyenburg, who has transitioned from his roles as President, CEO and Director and will continue to serve as an advisor to the Company. Additionally, the Company has initiated a process to evaluate strategic alternatives in order

      2/28/22 8:30:00 AM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gemini Therapeutics Announces Appointment of Georges Gemayel, Ph.D. as Chair of Board of Directors

      Gemini Therapeutics, Inc. (NASDAQ:GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD) and linked ocular disorders, today announced the appointment of Georges Gemayel, Ph. D., as the Chair of the Company's Board of Directors. "I am pleased to welcome Georges to Gemini's Board of Directors during this important time in our Company's maturation, as we advance our lead program into the next stages of clinical development," said Jason Meyenburg, Chief Executive Officer of Gemini Therapeutics. "Georges' broad management experience and proven track record of commercial and product development success wi

      5/3/21 7:00:00 AM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gemini Therapeutics Appoints Samuel Barone, M.D., as Chief Medical Officer

      Gemini Therapeutics, Inc. (NASDAQ:GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD) and linked ocular disorders, today announced the appointment of Samuel Barone, M.D., as Gemini's Chief Medical Officer, effective immediately. "We are thrilled to welcome Sam to Gemini as Chief Medical Officer, where he will bring his expertise as a board-certified ophthalmologist specializing in the treatment of retinal and macular diseases," said Jason Meyenburg, Chief Executive Officer of Gemini Therapeutics. "As we continue to advance our clinical pipeline, we will benefit tremendously from his two-plus deca

      4/12/21 8:00:00 AM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care